Cargando…

Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan

Detalles Bibliográficos
Autores principales:	Hashimoto, Takanao, Murayama, Anju, Mamada, Hanano, Saito, Hiroaki, Tanimoto, Tetsuya, Ozaki, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610564/ https://www.ncbi.nlm.nih.gov/pubmed/34826620 http://dx.doi.org/10.1016/j.cmi.2021.11.019

Ejemplares similares

Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
por: Mamada, Hanano, et al.
Publicado: (2023)

Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies
por: Murayama, Anju, et al.
Publicado: (2021)

Characteristics of Top-Searched Individuals in Japan’s Yen for Docs Conflicts of Interest Database During the COVID-19 Pandemic
por: Kaneda, Yudai, et al.
Publicado: (2023)

Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.
por: Kosaka, Makoto, et al.
Publicado: (2023)

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan
por: Saito, Hiroaki, et al.
Publicado: (2019)

Evaluation of Financial Conflicts of Interest and Quality of Evidence Underlying the American Diabetes Association Clinical Practice Guidelines: The Standards of Medical Care in Diabetes, 2021
por: Shigeta, Haruki, et al.
Publicado: (2023)

Financial Conflicts of Interest Among the Authors of the Clinical Practice Guidelines for Rheumatoid Arthritis in Japan
por: Murayama, Anju
Publicado: (2023)

How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
por: Ozaki, Akihiko, et al.
Publicado: (2022)

Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
por: Murayama, Anju, et al.
Publicado: (2020)

Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Delayed COVID-19 vaccine roll-out in Japan
por: Kosaka, Makoto, et al.
Publicado: (2021)

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019
por: Kamamoto, Sae, et al.
Publicado: (2023)

Trends in Industry Payments to Diabetologists and Endocrinologists in the United States During the COVID-19 Pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

Research and Nonresearch Industry Payments for COVID-19 mRNA Vaccines in the United States
por: Murayama, Anju, et al.
Publicado: (2023)

The Trend in Industry Payments During the COVID-19 Pandemic Among Gastroenterologists and Hepatologists in the United States
por: Murayama, Anju, et al.
Publicado: (2022)

Limited capacity of SARS-CoV-2 variants testing in Japan: A secondary analysis using publicly available data
por: Hashimoto, Takanao, et al.
Publicado: (2021)

Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians
por: Murayama, Anju, et al.
Publicado: (2022)

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Are the issues pointed out by ChatGPT can be applied to Japan? - Examining the reasons behind high COVID-19 excess deaths in Japan
por: Kaneda, Yudai, et al.
Publicado: (2023)

Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020
por: Murayama, Anju, et al.
Publicado: (2022)

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan
por: Sawano, Toyoaki, et al.
Publicado: (2019)

Japan’s Drug Regulation Framework: Aiming for Better Health or Bigger Profits?
por: Ozaki, Akihiko, et al.
Publicado: (2020)

Errors in the Conflict of Interest Disclosures Statement
Publicado: (2022)

Self-reported Financial Conflict of Interest in Nephrology Clinical Practice Guidelines
por: Chengappa, Madhuri, et al.
Publicado: (2020)

Financial Conflicts of Interest in Clinical Practice Guidelines: A Systematic Review
por: Tabatabavakili, Sahar, et al.
Publicado: (2021)

Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016
por: Shimada, Yuki, et al.
Publicado: (2019)

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Kusumi, Eiji, et al.
Publicado: (2022)

Will initial consultation patterns among undiagnosed cancer patients be the same after this COVID-19 pandemic? Experiences from the 2011 triple disaster in Fukushima, Japan
por: Ozaki, Akihiko, et al.
Publicado: (2020)

Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Negative Aspects of the Regional Quota System in Japan
por: Yamamoto, Kana, et al.
Publicado: (2019)

Japan's COVID-19 response: underutilized beds and misused funds
por: Saito, Yoshika, et al.
Publicado: (2023)

Eleven-Year Trend of Drug and Chemical Substance Overdose at a Local Emergency Hospital in Japan
por: Hashimoto, Takanao, et al.
Publicado: (2022)

Management of financial conflicts of interests in clinical practice guidelines in Germany: results from the public database GuidelineWatch
por: Napierala, Hendrik, et al.
Publicado: (2018)

A Call for Enhanced Healthcare Support for Increasingly Vulnerable Groups of Foreigners in Japan: Insights from a Former Thai-Native Medical Student in Japan
por: Supakul, Sopak, et al.
Publicado: (2021)

Transparency ethics in practice: Revisiting financial conflicts of interest disclosure forms in clinical practice guidelines
por: Lu, Yidan, et al.
Publicado: (2017)

Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension
por: Senoo, Yuki, et al.
Publicado: (2021)

Rethinking Japan’s Infallibility Principle for a Better Pandemic Response
por: Kaneda, Yudai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ht8pc3kvqt7e69b7t5n45gjc9n